Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Elixir Pharma
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Elixir Pharmaceuticals was a biotechnology company focused on the discovery and development of small molecule drugs to treat metabolic diseases and age-related disorders. Founded by pioneers in the field of aging research, the company's primary focus was on the sirtuin (SIRT1) pathway and the ghrelin receptor. Their lead programs included ghrelin receptor antagonists for the treatment of type 2 diabetes and obesity. Despite significant venture backing and high-profile scientific founders, the company ceased operations after failing to progress its pipeline through late-stage clinical trials.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Elixir Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elixir Pharma.